GMDA vs. WINT, EIGR, KRBP, ELOX, ACOR, TCBP, SCNI, FNCH, ALBT, and NSTGQ
Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include Windtree Therapeutics (WINT), Eiger BioPharmaceuticals (EIGR), Kiromic BioPharma (KRBP), Eloxx Pharmaceuticals (ELOX), Acorda Therapeutics (ACOR), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), Finch Therapeutics Group (FNCH), Avalon GloboCare (ALBT), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
50.3% of Gamida Cell shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 3.4% of Gamida Cell shares are held by insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Gamida Cell received 109 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 68.71% of users gave Gamida Cell an outperform vote while only 50.00% of users gave Windtree Therapeutics an outperform vote.
Gamida Cell has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
In the previous week, Windtree Therapeutics had 7 more articles in the media than Gamida Cell. MarketBeat recorded 7 mentions for Windtree Therapeutics and 0 mentions for Gamida Cell. Windtree Therapeutics' average media sentiment score of 0.81 beat Gamida Cell's score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
Gamida Cell presently has a consensus target price of $4.75, suggesting a potential upside of 30,348.72%. Given Gamida Cell's stronger consensus rating and higher probable upside, equities analysts clearly believe Gamida Cell is more favorable than Windtree Therapeutics.
Gamida Cell's return on equity of 0.00% beat Windtree Therapeutics' return on equity.
Windtree Therapeutics has lower revenue, but higher earnings than Gamida Cell. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Summary
Gamida Cell beats Windtree Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Gamida Cell News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gamida Cell Competitors List
Related Companies and Tools
